Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.730
-0.100 (-3.53%)
Nov 22, 2024, 4:00 PM EST - Market closed
Moleculin Biotech Stock Forecast
MBRX's stock price has decreased by -65.15% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Moleculin Biotech stock have an average target of 31, with a low estimate of 8.00 and a high estimate of 45. The average target predicts an increase of 1,035.53% from the current stock price of 2.73.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for MBRX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $20 → $8 | Strong Buy | Maintains | $20 → $8 | +193.04% | Nov 12, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $40 | Strong Buy | Maintains | $40 | +1,365.20% | Apr 12, 2024 |
| Maxim Group | Maxim Group | Strong Buy Maintains $45 → $20 | Strong Buy | Maintains | $45 → $20 | +632.60% | Mar 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +1,548.35% | Dec 14, 2023 |
| Roth MKM | Roth MKM | Strong Buy Maintains $240 | Strong Buy | Maintains | $240 | +8,691.21% | Apr 18, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-7.63
from -15.07
EPS Next Year
-5.99
from -7.63
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -7.85 | -6.16 | -6.06 |
| Avg | -7.63 | -5.99 | -5.89 |
| Low | -7.33 | -5.75 | -5.65 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.